- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05656495
Efficacy and Safety of Ambervin® and Standard Therapy in Hospitalized Patients With COVID-19
April 4, 2023 updated by: Promomed, LLC
An Open Randomized Multicenter Comparative Study to Evaluate the Efficacy, Safety and Tolerability of the Use of Ambervin® for Intramuscular Administration and for Inhalation in Patients Hospitalized With COVID-19
This is open-labe randomized multicenter comparative Phase III study conducted in 8 medical facilities.
The objective of the study is to assess the efficacy, safety and tolerability of Ambervin for intramuscular and inhaled administration in complex therapy COVID-19 compared with the Standard of care (SOC) in hospitalized patients with moderate COVID-19.
Study Overview
Status
Completed
Conditions
Detailed Description
Upon signing the informed consent form and screening, 313 eligible patients hospitalized with COVID-19 were randomized at a 1:1:1 ratio to receive either Ambervin intramuscular 1mg 1 times a day for 10 days or Ambervin inhaled 10mg 1 times a day for 10 days or SOC.
Study Type
Interventional
Enrollment (Actual)
313
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Cheboksary, Russian Federation
- Budgetary institution of the Chuvash Republic "Emergency Hospital"
-
Moscow, Russian Federation
- State Budgetary Healthcare Institution City Clinical Hospital named after S. I. Spasokukotskiy of Moscow Healthcare Department
-
Moscow, Russian Federation
- City clinical Hospital №24
-
Moscow, Russian Federation
- Infectious Clinical Hospital No.1
-
Ryazan, Russian Federation
- Regional Clinical Hospital
-
Ryazan, Russian Federation
- Ryazan State Medical University named after academician I.P. Pavlov of Ministry of Health of the Russian Federation
-
Saransk, Russian Federation
- Ogarev Mordova State University of Ministry of Health of the Russian Federation
-
Sestroretsk, Russian Federation
- City Hospital No. 40 Kurortny District
-
Smolensk, Russian Federation
- Regional State Budget Healthcare Institution "Clinical hospital No. 1"
-
Voronezh, Russian Federation
- Voronezh Regional Clinical Hospital No.1
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Availability of the Informed Consent Form of thePatient Information Leaflet (PIL) signed and dated bypatient.
- Men and women aged 18 to 80 years inclusive at thetime of signing the Informed Consent Form in PIL.
- Confirmed case of COVID-19 at the time ofscreening based on SARS-CoV-2 RNA test usingnucleic acid amplification (NAA) method. It isacceptable to include a patient with a presumptiveCOVID-19 diagnosis prior to receiving the results ofSARS-CoV-2 RNA test made at the screening stage.
- Hospital admission due to COVID-19.
Moderate severity infection with SARS-CoV-2: Clinical signs (the presence of at least 2 of the following criteria):
- body temperature > 38 °C;
- RR > 22/min;
- CT pattern typical of a viral lesion
- shortness of breath on exertion;
- SpO2 < 95%;
- Serum CRP > 10 mg/L.
- Lesion volume is minimal or moderate; CT 1-2.
- Patient's consent to use reliable contraceptive methods through out the study and within 1 month for women and 3 months for men after its completion. Reliable means of contraception are: sexualabstinence, use of condom in combination withspermicide.
Women incapable of childbearing may also participate inthe study (with past history of: hysterectomy, tubal ligation,infertility, menopause for more than 2 years), as well asmen with infertility or a history of vasectomy
Exclusion Criteria:
- Hypersensitivity to components of the study drug.
- Impossibility of CT procedure (for example, gypsumdressing or metal structures in the field of imaging).
- Obstacles or inability to perform intramuscular injections and / or inhalations
- Arterial hypotension (a decrease in blood pressure (BP) below 100/60 mm Hg) at the time of screening and / or a history of hypotensive crises.
- The need for the use of drugs from the list of prohibited therapies.
- Availability of criteria for severe and extremely severe disease at the time of screening
- Presence within 6 months prior to screening of a probable or confirmed case of moderate COVID-19
- History of presumptive or confirmed COVID-19 caseof moderate, severe and extremely severe course ofthe disease.
- Vaccination less than 4 weeks prior to screening.
- The need for treatment in the intensive care unit at the time of screening.
- Impaired liver function (AST and/or ALT ≥ 2 UNLand/or total bilirubin ≥ 1.5 UNL) at the time ofscreening.
- Renal impairment (GFR < 60 ml/min) at the time of screening.
- Positive testing for HIV, syphilis, hepatitis B and/or C.
- Chronic heart failure FC III-IV according to New York Heart Association (NYHA) functional classification.
- Malignancies in the past medical history.
- Alcohol, pharmacological and/or drug addiction in the past medical history and/or at the time of screening.
- Epilepsy in history.
- Schizophrenia, schizoaffective disorder, bipolardisorder, or other history of mental pathology orsuspicion of their presence at the time of screening.
- Severe, decompensated or unstable somatic diseases (any disease or condition that threaten thepatient's life or impair the patient's prognosis, and also make it impossible for him/her to participate in the clinical study).
- Any history data that the investigating physician believes could lead to complication in the interpretation of the study results or create an additional risk to the patient as a result of his/her participation in the study.
- Patient's unwillingness or inability to comply with procedures of the Study Protocol (in the opinion of physician investigator).
- Pregnant or nursing women or women planning pregnancy.
- Participation in another clinical study for 3 monthsprior to inclusion in the study.
- Other conditions that, according to the physicianinvestigator, prevent the patient from being includedin the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ambervin intramuscularly
Arm 1 (n=104) receives the study drug Ambervin for intramuscularly administration 1 mg 1 time per day.
The course of treatment is 10 days.
|
lyophilizate for preparation of solution for intramuscular administration 1 mg 1 time per day for 10 days
Other Names:
|
Experimental: Ambervin inhaled
Arm 2 (n=105) receives the study drug Ambervin for inhalation administration 10 mg 1 time per day.
The course of treatment is 10 days.
|
lyophilizate for preparation of solution for inhalation administration 10 mg 1 time per day for 10 days
Other Names:
|
Active Comparator: Standard of care
Arm 3 (n=104) patients receive standard therapy prescribed in accordance with the recommended treatment regimens included in the InterimGuidelines for the prevention, diagnosis and treatment of new coronavirus infection (COVID-19) approved by the Russian Ministry of Health by decision of the investigator and taking into account the availability of drugs at the study site
|
The administration of 'StandardTherapy' drugs was done according to the regimen recommended in the 'COVID-19TreatmentGuidelines'(current version)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Prevalence of patients with category 0-1 as per categorical ordinal clinical improvement WHO scale
Time Frame: From baseline to Visit 4 (days 14-15)
|
The proportion of patients with category 0-1 as per the categorical ordinal clinical improvement scale
|
From baseline to Visit 4 (days 14-15)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Prevalence of patients with clinical status less than 4 points on the categorical ordinal WHO scale of clinical improvement
Time Frame: From baseline to Visit 3 (days 11-12) and 4 (days 14-15)
|
The proportion of patients with clinical status less than 4 points on the categorical ordinal WHO scale of clinical improvement
|
From baseline to Visit 3 (days 11-12) and 4 (days 14-15)
|
Frequency of improvement in clinical status on a categorical ordinal WHO scale of clinical improvement of 2 or more categories
Time Frame: From baseline to Visit 3 (days 11-12) and 4 (days 14-15)
|
The proportion of patients with clinical status on a categorical ordinal WHO scale of clinical improvement of 2 or more categories
|
From baseline to Visit 3 (days 11-12) and 4 (days 14-15)
|
Time to improve clinical status on a categorical ordinal scale of clinical improvement by ≥ 1 point.
Time Frame: From baseline to Visit 6 (study completion, day 28±1)
|
Number of days to improve clinical status on a categorical ordinal scale of clinical improvement by ≥ 1 point.
|
From baseline to Visit 6 (study completion, day 28±1)
|
Prevalence of patients eligible for discharge to continue outpatient treatment according to BMR
Time Frame: From baseline to Visit 2 (days 6-7), 3 (days 11-12)
|
The proportion of patients eligible for discharge to continue outpatient treatment according to current Cuidelines
|
From baseline to Visit 2 (days 6-7), 3 (days 11-12)
|
Prevalence of patients with RR < 22/min
Time Frame: From baseline to Visit 2 (days 6-7), 3 (days 11-12)
|
The proportion of patients with RR < 22/min
|
From baseline to Visit 2 (days 6-7), 3 (days 11-12)
|
Prevalence of patients with CRP level < 10 mg/l
Time Frame: From baseline to Visit 2 (days 6-7), 3 (days 11-12)
|
The proportion of patients with CRP level < 10 mg/l
|
From baseline to Visit 2 (days 6-7), 3 (days 11-12)
|
Prevalence of patients with blood lymphocytes > 1.2 x 10(9)/L
Time Frame: From baseline to Visit 2 (days 6-7), 3 (days 11-12)
|
The proportion of patients with blood lymphocytes > 1.2 x 10(9)/L
|
From baseline to Visit 2 (days 6-7), 3 (days 11-12)
|
Assessment of the degree of lung damage according to CT
Time Frame: From baseline to Visit 4 (days 14-15)
|
The degree of lung damage according to CT
|
From baseline to Visit 4 (days 14-15)
|
Prevalence of patients with SpO2 ≥ 95% on 2 consecutive days
Time Frame: From baseline to Visit 2 (days 6-7), 3 (days 11-12), 4 (days 14-15)
|
The proportion of patients with SpO2 ≥ 95% on 2 consecutive days
|
From baseline to Visit 2 (days 6-7), 3 (days 11-12), 4 (days 14-15)
|
The frequency of transfer of patients to the intensive care unit and intensive care
Time Frame: From baseline to Visit 6 (study completion, day 28±1)
|
The proportion of patients transferred to the intensive care unit and intensive care
|
From baseline to Visit 6 (study completion, day 28±1)
|
The frequency of cases of the use of high flow oxygen therapy, non-invasive and invasive ventilation of lung, ECMO
Time Frame: From baseline to Visit 6 (study completion, day 28±1)
|
The proportion of patients who used high flow oxygen therapy, non-invasive and invasive ventilation of lung, ECMO
|
From baseline to Visit 6 (study completion, day 28±1)
|
The frequency of cases of ARDS
Time Frame: From baseline to Visit 6 (study completion, day 28±1)
|
The proportion of patients with ARDS
|
From baseline to Visit 6 (study completion, day 28±1)
|
The frequency of patients with a fatal outcome
Time Frame: From baseline to Visit 6 (study completion, day 28±1)
|
The proportion of patients with a fatal outcome
|
From baseline to Visit 6 (study completion, day 28±1)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Dmitriy Pushkar, Moscow State Clinical Hospital №50
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- L.A. Balykova, O.A. Radaeva, K.Ya. Zaslavskaya, P.A. Bely, V.F. Pavelkina, N.A. Pyataev, A.Yu. Ivanova, G.V. Rodoman, N.E. Kostina, V.B. Filimonov, E.N. Simakina, D.A. Bystritsky, A.S. Agafina, K.N. Koryanova, D.Yu. Pushkar. Efficacy and safety of original drug based on hexapeptide succinate in complex COVID-19 therapy in adults hospitalized patients. Pharmacy & Pharmacology. 2022;10(6):573-588. DOI: 10.19163/2307-9266-2022-10-6-573-588
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 28, 2022
Primary Completion (Actual)
November 22, 2022
Study Completion (Actual)
November 22, 2022
Study Registration Dates
First Submitted
December 15, 2022
First Submitted That Met QC Criteria
December 15, 2022
First Posted (Actual)
December 19, 2022
Study Record Updates
Last Update Posted (Actual)
April 6, 2023
Last Update Submitted That Met QC Criteria
April 4, 2023
Last Verified
April 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AMB-112021
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States